Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.33 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11964062 | 0.93 | AKT1 (0.42) | SIRT2AKT1GLP1RSIRT1SIRT3 | |
| SCHEMBL14755924 | 0.91 | AKT1 (0.41) | SIRT2AKT1GLP1RSIRT1SIRT3 | |
| SCHEMBL17488484 | 0.85 | AKT1 (0.40) | SIRT2AKT1GLP1RSIRT1SIRT3 | |
| SCHEMBL18084214 | 0.85 | AKT1 (0.42) | SIRT2AKT1GLP1RSIRT1SIRT3 | |
| SCHEMBL14542727 | 0.85 | AKT1 (0.36) | SIRT2AKT1SIRT1 | |
| SCHEMBL12389311 | 0.83 | SIRT2 (0.42) | SIRT2AKT1SIRT1SIRT3TPSAB1 | |
| SCHEMBL277647 | 0.82 | SIRT2 (0.45) | SIRT2AKT1SIRT1SIRT3TPSAB1 | |
| SCHEMBL18480125 | 0.80 | AKT1 (0.39) | SIRT2AKT1GLP1RSIRT1SIRT3 | |
| SCHEMBL15445007 | 0.80 | SIRT2 (0.38) | SIRT2GLP1RSIRT1SIRT3TPSAB1 | |
| SCHEMBL14016183 | 0.80 | AKT1 (0.40) | SIRT2AKT1SIRT1SIRT3CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8454959-B2 | Compositions monovalent for CD28 binding and methods of use | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120201814-A1 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE | DOMANTIS LTD. (GB) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120201814-A1 | COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE | CD69, CD40LG, CD40 | SIRT2 3484/4885AKT1 2929/4885GLP1R 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.